Daridorexant Safe, Effective for Insomnia Disorder

FRIDAY, Feb. 4, 2022 (HealthDay News) -- Daridorexant (50 mg) improves both nighttime symptoms and daytime functioning in people with insomnia disorder, according to a study published in the Feb. 1 issue of The Lancet Neurology.
Emmanuel Mignot, M.D., from the Stanford Center for Sleep Research and Medicine in Palo Alto, California, and colleagues conducted two phase 3 randomized controlled trials at 156 sites in 17 countries. The authors randomly assigned 930 adults with insomnia disorder (1:1:1) to receive either daridorexant (50 mg, 25 mg) or placebo in study 1 and 924 adults to receive either daridorexant (25 mg, 10 mg) or placebo in study 2 every evening for three months.
The researchers found that in study 1, wake time after sleep onset (WASO) and latency to persistent sleep (LPS) were significantly reduced among participants in the daridorexant 50-mg group versus participants in the placebo group at month 1 and month 3. Similar results for WASO and LPS were seen among those receiving daridorexant 25 mg versus the placebo group. The daridorexant 50-mg group also had significantly improved self-reported total sleep time and Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) scores at month 1 and month 3 compared with placebo. However, the daridorexant 25-mg group only saw significant improvements in self-reported total sleep, not IDSIQ sleepiness domain scores. In study 2, WASO was significantly reduced in the daridorexant 25-mg group versus placebo at month 1 and month 3, but there were no significant differences seen in LPS. The daridorexant 25-mg group saw significant improvement in self-reported total sleep time at month 1 and month 3, but not in IDSIQ sleepiness domain scores at either timepoint. No significant improvements for any measures were seen for the daridorexant 10-mg group versus placebo. The overall incidence of adverse events was similar between treatment groups across studies.
"It is exciting to see that insomnia is finally not solely viewed as a nighttime problem but as a cause of daytime suffering," Mignot said in a statement.
Several authors disclosed financial ties to pharmaceutical companies, including Idorsia Pharmaceuticals, which manufactures daridorexant and funded the study.
Abstract/Full Text (subscription or payment may be required)
Related Posts
Philadelphia Lifts Indoor Mask Mandate Enacted Four Days Ago
FRIDAY, April 22, 2022 (HealthDay News) -- The indoor mask mandate that was...
Estados Unidos reanuda el programa gratuito de pruebas de COVID
VIERNES, 22 de septiembre de 2023 (HealthDay News) -- Los estadounidenses podrán...
Smoking Tied to Higher Risk for Severe COVID-19
FRIDAY, July 29, 2022 (HealthDay News) -- Smoking is associated with a higher...
Keep Wearing Masks a While Longer, CDC Director Says
WEDNESDAY, Feb. 9, 2022 (HealthDay News) -- Many states are already dispensing...